Physician profile
Mohammad Dada
NPI 1457307043
$11,407.17
in general payments reported to CMS, 2019-2025
29 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $601 · 2021: $1,241 · 2022: $1,532 · 2023: $3,998 · 2024: $1,389 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,374 · Travel and Lodging: $765 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,374.33 |
| Travel and Lodging | $764.55 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,420.05 | 2021-2025 | Vraylar |
| Neuronetics, INC. | $1,313.79 | 2023 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $906.48 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $852.02 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $795.34 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $768.66 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $621.15 | 2020-2025 | Austedo, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $499.55 | 2019-2025 | Rexulti |
| Alkermes, INC. | $496.25 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $472.22 | 2020-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $405.29 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $333.33 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $314.20 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $238.72 | 2024-2025 | Cobenfy |
| Corium, LLC | $142.73 | 2022-2023 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.55 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $99.66 | 2024-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $95.93 | 2019-2022 | |
| Eisai INC. | $88.79 | 2020-2022 | |
| Indivior INC. | $86.44 | 2019-2025 | Sublocade |
| Shire North American Group INC | $70.82 | 2019 | |
| Almatica Pharma LLC | $69.29 | 2021-2022 | |
| Bausch Health US, LLC | $55.60 | 2021-2023 | Wellbutrin, Aplenzin |
| Luye Pharma (USA) Ltd. | $37.83 | 2025 | Erzofri Extended-Release |
| Avanir Pharmaceuticals, INC. | $34.42 | 2019-2022 | |
| Orexo US, INC. | $24.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.23 | 2021 | |
| Noven Therapeutics, LLC | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.